Invention Grant
US09328091B2 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
有权
5H-环戊二烯并[d]嘧啶作为AKT蛋白激酶抑制剂
- Patent Title: 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
- Patent Title (中): 5H-环戊二烯并[d]嘧啶作为AKT蛋白激酶抑制剂
-
Application No.: US14523481Application Date: 2014-10-24
-
Publication No.: US09328091B2Publication Date: 2016-05-03
- Inventor: Anna Leivers , Josef R. Bencsik , James F. Blake , Martin F. Hentemann , Nicholas C. Kallan , Jun Liang , Ian S. Mitchell , Stephen T. Schlachter , Eli M. Wallace , Rui Xu , Tony P. Tang
- Applicant: Array BioPharma Inc. , Genentech, Inc.
- Applicant Address: US CA South San Francisco US CO Boulder
- Assignee: GENENTECH, INC.,ARRAY BIOPHARMA INC.
- Current Assignee: GENENTECH, INC.,ARRAY BIOPHARMA INC.
- Current Assignee Address: US CA South San Francisco US CO Boulder
- Agency: Viksnins Harris & Padys PLLP
- Main IPC: C07D239/70
- IPC: C07D239/70 ; C07D401/10 ; C07D401/04 ; C07D409/04 ; C07D417/04 ; C07D487/04 ; C07D401/12 ; C07D403/04 ; C07D403/10 ; C07D417/10 ; C07D211/08 ; C07D211/46
![5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors](/abs-image/US/2016/05/03/US09328091B2/abs.jpg.150x150.jpg)
Abstract:
Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Public/Granted literature
- US20150266852A1 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS Public/Granted day:2015-09-24
Information query